TO: EZIZ Users
FROM: CDPH
SUBJECT: Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years
DATE: 9/19/14

ACIP now recommends pneumococcal conjugate vaccine (PCV13; trade name prevnar 13) as well as pneumococcal polysaccharide vaccine (PPSV23; trade name pneumovax) for all adults aged ≥65 years (Box). Those who have not previously received pneumococcal vaccine or whose vaccination history is unknown should receive a dose of PCV13 first, followed at least 6 months later by a dose of PPSV23. The two vaccines should not be co-administered. The minimum acceptable interval between PCV13 and PPSV23 is 8 weeks.

Previous vaccination with PPSV23. Adults aged ≥65 years who have previously received ≥1 dose of PPSV23 and who have not yet received PCV13 should receive a dose of PCV13 at least 1 year after receipt of their most recent PPSV23 dose. When an additional dose of PPSV23 is indicated, it should be given 6-12 months after PCV13 and ≥5 years after the most recent dose of PPSV23. ACIP recommendations remain unchanged for the routine use of PCV13 in adults aged ≥19 years with any of

- immunocompromising conditions
- functional or anatomic asplenia
- cerebrospinal fluid leak
- cochlear implants

If you would like to be removed from the EZIZ list-serve, please go to http://eziz.org/manage-subscription.php to unsubscribe.